Thomas Jefferson University

Jefferson Digital Commons
Department of Neurology Faculty Papers

Department of Neurology

9-10-2015

A prospective highlight on exosomal nanoshuttles and cancer
immunotherapy and vaccination.
Mohammad Rafi
Department of Neurology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA
19107

Yadollah Omidi
Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical
Sciences, Tabriz, Iran

Follow this and additional works at: https://jdc.jefferson.edu/neurologyfp
Part of the Other Medical Specialties Commons

Let us know how access to this document benefits you
Recommended Citation
Rafi, Mohammad and Omidi, Yadollah, "A prospective highlight on exosomal nanoshuttles and
cancer immunotherapy and vaccination." (2015). Department of Neurology Faculty Papers.
Paper 88.
https://jdc.jefferson.edu/neurologyfp/88
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Neurology Faculty Papers by an authorized administrator of the Jefferson
Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Rafi M.A., Omidi Y., BioImpacts, 2015, 5(3), 117-122

TUOMS

doi: 10.15171/bi.2015.22
BioImpacts

Publishing
Group

http://bi.tbzmed.ac.ir/

Publish Free

ccess

A prospective highlight on exosomal nanoshuttles and cancer
immunotherapy and vaccination
Mohammad A. Rafi1 , Yadollah Omidi2*

Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvanian
19107, USA
2
Research Center for Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
1

Article Info

Article Type:
Prospective Highlights
Article History:
Received: 17 Aug. 2015
Revised: 28 Aug. 2015
Accepted: 05 Sept. 2015
ePublished: 10 Sept. 2015
Keywords:
Cancer immunotherapy
Cancer vaccination
Exosomes
Extracellular vesicles
Vesicular trafficking

Abstract
Introduction: Exosomes (EXOs) and ectosomes (ECTOs) are
nanoscale membranous extracellular vesicles (EVs) derived
from different cells mediating various cellular communications.
EXOs are liberated based on the exocytosis of multivesicular
bodies, while ECTOs are ubiquitously released from the plasma
membranes.
Methods: Here, in this paper, we go over the extracellular
vesicular machineries and concisely highlight their clinical
importance in solid tumors and their possible applications in
cancer immunotherapy/vaccination.
Results: In various types of cancers, these vesicles play central roles delivering cancer cell messages
to the target cells, as a result both of them seem to provide a novel useful means for diagnosis and
therapy of malignancies. Dendritic cell-derived exosomes (DEXOs) are able to activate the tumor
antigen-specific CD8+ cytotoxic T-lymphocytes (CTLs) and hence induce antitumor responses
in vivo. Within the tumor microenvironment (TME), however, tumor cells seem to generate
exosomes (the so-called oncosoems) that may act in favor of tumor progression.
Conclusions: As complex systems, these vesicular micro-/nano-machines convey important
cellular messages dependent upon the cells/tissue setting(s). In addition to their potential in
diagnosis of cancers, they have been exploited for cancer immunotherapy/vaccination. However,
such treatment strategies need to be carefully designed to attain desired clinical outcomes.

Introduction
The epigenetic and genetic reprogramming or
modifications due to the genomic instability are thought
to be the fundamental features of tumorigenesis. These
modifications result in the expression of abnormal or
mutated proteins. Therefore, the antigenic characteristics
of the tumor cells can be perceived by the innate and
cognate immune systems - a phenomenon known
as immunosurveillance.1 However,
it should be
pointed out that the cancer cells are able to adopt
some crucial mechanisms to secure their survival,
proliferation, progression and invasion even after chemo/
immunotherapy. These strategies may manifest by emerging
their own growth signals, resisting to growth-inhibitory
signals, challenging apoptotic processes, preserving their
replicative potentials, sustaining angiogenesis, and finally,
migrating by metastatic invasion and colonizing into the
neighboring tissues and organs.2 In fact, cancer cells are able
to escape the immunosurveillance functions of immune
system through immunomodulation, immunoselection/

immunoediting and immunosubversion.3 In addition,
solid tumors attain unique capability to create a permissive
milieu – the so-called tumor microenvironment (TME)
– to escape such immunosurveillance. TME is often
associated with aberrant metabolisms (e.g., anomalous
consumption of glucose and L-tryptophan), emergence
of irregular microvasculature and modified interstitium
with high pressure fluid that impose significant
pathophysiologic barrier functions against cancer
treatment modalities.4,5 Further, within TME, tumor cells
impose immunosuppressive functions via regulatory T
(Treg) cells and/or myeloid-derived suppressor cells and
downregulation of major histocompatibility complex
(MHC) expression.1,6 The malignant cells, unlike normal
cells, are able to escape the anoikis7,8 during metastasis,
while their death can hardly ever induce any immune
responses against tumor cell derived antigens.
As one of intriguing mechanisms, cancer cells exploit
membranous vesicles machineries for communication
with the neighboring cells. These cellular communication
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machineries are known as exosomes (EXOs) and
ectosomes (ECTOs), which are micro-/nano-scaled
vesicles secreted from various cells to convey messages
related to immune responses and signal transductions.9
Biogenesis of extracellular vesicles
The biogenesis of bioactive EXOs commences with the
fusion of multivesicular bodies (MVBs) with the plasma
membrane and release of intraluminal vesicles (ILVs) as
EXOs.10 This phenomenon, which was initially observed
as a mechanism for the removal of transferrin receptor
during maturation of reticulocytes, is now considered
as an alternative secretory pathway of the endocytic
network; readers are directed to see a previously
published book chapter on “Biological membranes
and barriers” for the vesicular trafficking.11 In fact, the
MVBs are intermediate cellular compartments originated
from endosomes through invagination of the limiting
endosomal membrane. The ILVs, which are not yet
released to the extracellular space, can drive the formation
of EXOs (50-100 nm in diameter) that are released on
the exocytosis of MVBs. Unlike EXOs, the ECTOs (50350 nm in diameter) are ubiquitous vesicles assembled
at and released from the plasma membrane.12 The fusion

of liberated EVs with target cells is initiated through
interaction of the external faces of cell membranes, which
is mediated by fusogens such as syncytin-1. Both EXOs
and ECTOs show rolling and membrane fusion potential
with rapid dissolution and specific markers such as CD63
and CD61 for EXOs, and TyA and C1q for ECTOs.12 Fig. 1
represents schematic illustration of various extracellular
vesicles in communication with other cells such as B
and T lymphocytes and the biogenesis of such vesicular
machineries.
EXOs derived from dendritic cells (DCs) are
known as dexosomes (DEXOs) that contain ligands
capable of activating the natural killer (NK) cells.
Immunomodulatory impacts of DEXOs provide
possibility towards development of reprogramed DEXOs
for the specific activation of immune system including
invariant Natural killer T (NKT) cells and antigen-specific
T and B lymphocytes.13 As shown in Fig. 1 (panel A),
compelling evidences have shown that tumor antigenloaded DEXOs are able to activate the tumor antigenspecific CD8+ cytotoxic T-lymphocytes (CTLs) and
hence induce antitumor responses in animal models
and human clinical trials.14 However, it appaers that
there exist somewaht controversies upon the impacts

Fig. 1. Schematic illustration of extracellular vesicles in solid tumors. A) Tumor cells-derived exosomes (TEXOs) and dendritic cellsderived exosomes (DEXOs) in tumor microenvironment of small intestine cancer. B) Extracellular vesicles (EVs) communication with B
and T lymphocytes. C) Biogenesis of exosomes (EXOs) and ectosomes (ECTOs) in dendritic cells.
118

BioImpacts, 2015, 5(3), 117-122

Cancer immunotherapy and vaccination: impacts of exosomes

of the EVs, perhaps becuase of the tumor cells-derived
exosomes (TEXOs) that is favor of cancer progreesion.
For the biogenesis of EXOs (Fig. 1C), transmembrane
proteins should be endocytosed and transferred into the
early endosomes. While the “endosomal sorting complex
required for transport” (ESCRT) for the early endosomal
sorting (ESCRT-0) involves ubiquitinated proteins,
sorting of the late endosome by intraluminal vesicles
(ILVs) and forming of the multivesicular bodies (MVBs)
are mediated by ESCRT-I and –II. Then, as demonstrated
in Fig. 1 (panels B and C), the formed MVBs can undergo
either the liberation of ILVs (i.e., through exocytosis of
EXOs to the extracellular space) or the degradation of
ILVs (i.e., via fusion of MVBs with lysosomes).
For the formation of ECTOs (Fig. 1C), transmembrane
proteins (e.g., tetraspanins, matrix metalloproteinase
MT1-MMP, integrins, receptor agonists) are assembled
in distinct membrane domains creating some kind of
molecular raft – key to outward membrane budding.
This occurs in association with lipidic anchors (e.g.,
myristoylation, palmitoylation) of proteins, and the Ca2+activated scramblases that randomize the distribution of
lipids. Then, the cytoskeleton becomes limper and various
cytosolic proteins and RNA molecules are sustained
within the vesicles. The ECTOs are then pinched off,
in which TSG101, a member of the ESCRT-I complex,
mediates mobilization of ESCRT-III towards plasma
membrane facilitating the assembly of a spiral form
structure. This structure is disassembled by ATPase VPS4,
and finally ECTOs are liberated, readers are directed to a
comprehensive review published recently by Cocucci and
Meldolesi.12
Clinical impacts of EVs
It should be articulated that the cancer-derived EVs
encompass biological information and elements (e.g.,
receptors, enzymes, biomarkers, reactive oxygen species,
genetic markers) as well as a number of key oncogenes
and RNA molecules that can induce proneoplastic effects.
The contents of normal and cancer cells-generated EVs
show marked differences. Large TEXOs (the so-called
oncosomes) were shown to mediate intercellular transfer
of distinct classes of functional microRNA, namely,
enhanced migration of cancer-associated fibroblasts
(CAFs) by miR-1227. Among the proteins enriched in
TEXOs, cytokeratin 18 (CK18) was reported as one of the
most abundant oncomarkers found in the circulation and
tissues of prostate cancer cases.15 Through secretion of
TEXOs, the migrating tumor cells happen to condition the
distant sites to make them permissive for colonizing and
thereby advancing the disease.16 It should be pointed out
that cancer-originated EVs display marked ability to elicit a
rapid tissue growth, while other extracellular vesicles (e.g.,
DEXOs) can impose tumor suppressor potentials. Thus, it
seems that the vesicular nanomachines, depending on the
cell origin, are able to shuttle bioelements to the target cells,
which can either promote or suppress the cancer-related
phenotypes.12 Of note, TEXOs enriched in patients’ sera

can be isolated and used as a reliable individual-specific
source of antigens to load DCs. Such antigen-loaded DCs
can be exploited as personalized anticancer vaccination
modality.17
In addition to the cell-based vaccination and
immunotherapy of cancer using re-programed
individualized DCs, the DEXOs were shown to provide
well-tolerated promising modalities for vaccination against
malignancies.18 Recently, in a phase I/II clinical trial, seven
patients with advanced stage of squamous cell carcinoma
of esophagus were treated with a vaccine comprised of
monocyte-derived dendritic cells (moDCs) pulsed with
SART1 peptide. It was found that the vaccine was able to
induce SART1 peptide-specific cytotoxic T lymphocytes
(CTLs) while the moDCs were able to liberate DEXOs
capable of inducing SART1 peptide-specific CTLs.19
However, the efficacy of DEXOs-based immunotherapy
against cancer depends on the responsiveness of both
B and T lymphocytes, which is in turn reliant upon the
presence of both T- and B-cell DEXO-associated epitopes.20
DEXOs contain various proteins and lipid necessary for
biological functions of EVs. Among these components,
immunorelevent molecules such as MHC molecules,
costimulatory molecules, heat shock proteins (HSP),
and peptide antigens are responsible for striking role of
DEXOs in T cell (CD8+ and CD4+ ) dependent anti-tumor
immune response stimulation. Several studies confirmed
potential effects of EXOs loaded antigen to eradicate
tumor in vitro, ex vivo and in vivo, in which addition
of immune stimulation components (TLRs agonists,
bacterial/viral peptides) may enhance the immune
response. For instance, incorporation of the G protein of
vesicular stomatitis virus into EXOs co-expressed with
antigen was shown to improve (a) maturation of active
DCs, (b) stimulation of antigen specific responses of
CTLs, (c) upregulation of costimulatory molecules (CD80,
CD86, CD40), (d) generation of IL12 as a DC effector, and
(e) acceleration of antigen internalization by endocytosis
following presenting by the MHC class I.21
Up until now, capitalizing on clinical potential of EVs,
a number of clinical trials have been settled. The first
clinical trial study supported by the Institute Gustave
Roussy in France was performed using autologous EXOs
pulsed with MAGE 3 peptides for the immunization of
stage III/IV melanoma patients. In this study, fifteen
HLA-A1+, B35+, HLA DPO4+ metastatic melanoma
patients expressing MAGE3 antigen on tumor cells were
undergone the trail, and the autologous DEXOs pulsed
with MHC class I-peptide or MHC class II –peptide
were administered subcutaneously/intradermally in
different dosages (4 times weekly). No major toxicity was
observed in patients under such immunization modality.
The results showed that, in contrast to insignificant
increased percentage of peripheral blood lymphocyte and
undetectable MAGE3 specific T lymphocyte response,
nor Th neither Tc induction of NK cell functions boosted
in these patients.22 Table 1 lists some of the EXOs-based
clinical trials conducted for diagnosis and/or therapy of
BioImpacts, 2015, 5(3), 117-122 119

Rafi and Omidi
Table 1. List of the exosome-based clinical trials conducted for diagnosis and/or therapy of different malignancies
Trial ID: Description

Cancer type

Intervention/Experiment

Sponsor

NCT01779583: Circulating Exosomes As Potential Prognostic
And Predictive Biomarkers In Advanced Gastric Cancer Patients
("EXO-PPP Study")
NCT02393703: Interrogation of Exosome-mediated
Intercellular Signaling in Patients With Pancreatic Cancer

Gastric Cancer

Molecular profile in
tumor derived exosomes

Hospital Miguel
Servet

Pancreatic Cancer

Exosomes purification for
downstream applications
(e.g., proteomics and RNA
sequencing)

Memorial Sloan
Kettering Cancer
Center

NCT01668849: Edible Plant Exosome Ability to Prevent Oral
Mucositis Associated With Chemoradiation Treatment of Head
and Neck Cancer
NCT02147418: Exosome Testing as a Screening Modality for
Human Papillomavirus-Positive Oropharyngeal Squamous Cell
Carcinoma
NCT01294072: Study Investigating the Ability of Plant
Exosomes to Deliver Curcumin to Normal and Colon Cancer
Tissue
NCT02071719: Prediction of Response to Kinase Inhibitors
Based on Protein Phosphorylation Profiles in Tumor Tissue
From Advanced Renal Cell Cancer Patients
NCT02310451: Study of Molecular Mechanisms Implicated in
the Pathogenesis of Melanoma

Head and Neck Cancer;
Oral Mucositis

Dietary supplement:
grape extract

James Graham Brown
Cancer Center

Oropharyngeal Cancer

Exosome protein
signature outcome
measure
Dietary supplement:
curcumin conjugated with
plant exosomes
Tumor exosomes from
urine and serum

New Mexico Cancer
Care Alliance

Metastatic Melanoma

Blood test

Centre Hospitalier
Universitaire de Nice

NCT02464930: Evaluation of MicroRNA Expression in Blood
and Cytology for Detecting Barrett's Esophagus and Associated
Neoplasia

Barrett's Esophagus;
Gastroesophageal
Reflux; Esophageal
Adenocarcinoma
Malignant Glioma of
Brain

Sensitivity and specificity
of tissue and serum
microRNA expression

Midwest Biomedical
Research Foundation

IGF-1R/AS ODN

Thomas Jefferson
University

NCT01550523: Pilot Immunotherapy Trial for Recurrent
Malignant Gliomas

Colon Cancer

Renal Cell Cancer

James Graham Brown
Cancer Center
VU University
Medical Center

Data were obtained from clinicaltrials.gov website. All clinical trials listed were in recruiting phase.

various malignancies.
It should be pinpointed that an effective tumor specific
immune response within TME needs activation of both
innate and adaptive immune systems through cellular
(i.e., induction of natural killer (NK) cells, cytotoxic
CD8+T cells and gamma delta T cells) and humoral such
as antibody-dependent cellular cytotoxicity (ADCC)
immune responses.13 However, the penetration of whole
monoclonal antibodies (mAbs) into TME seems to be
largely size-dependent in large part due to high oncotic
pressure within TME, and often a population of cancer cells
in the core of solid tumors appears to remain untouched
that can be the main cause of disease relapse. To overcome
these anomalous pathophysiologic traits of solid tumors,
novel cancer therapy strategies have been implemented
including
multifunctional
nanomedicines,23-39
multispecific antibody (Ab) scaffolds,40-42 and various
vaccination strategies such as edible vaccines.43 It should
be stated that the selection of effective mAbs for cancer
immunotherapy appears to be very laborious and
sophisticated,44-46 while nanocarriers used in formulation
of nanomedicines may induce inevitable toxic impacts
nonspecifically.47-53
Final remarks
It appears that EXOs, TEXOs (small and large oncosomes)
and DEXOs are important cellular micro-/nanomachineries that are involved in many cellular functions.
Based on the cell origin, in malignancies, these EVs convey
120
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various messages to promote or to inhibit antitumor
responses. Despite plethora of investigations on various
EVs, it seems we still need to fully decode the main
messages of these silently whispering vesicles and examine
their potentials in diagnosis and treatment of diseases (in
particular malignancies) in which the involved cells use
such intricate bio-machineries for their communications.
The conducted studies together with the growing body
of evidence indicate that EXOs provide great potentials
as a novel nanoscale cellular machineries for various
diagnostic and therapeutic purposes. However, there exist
some striking questions to be addressed. What if these
EVs convey signals to suppress the immunosurveillance
or danger signals to make TME much more permissive?
Is it likely that they shuttle danger signals to neighboring
cells/tissue? Do the malignant cells use such capacity
for the migration and hence colonization into the
neighboring cells/tissue? What are the main roles of lipid
rafts , membranous caveolae and clathrin coated-pitsd
in this process? Taken all, in the best scenario, we may
capitalize on these cell-free vaccination system. And, if we
exploit these paramount and worth pursuing nanoshuttles
for cancer immunotherapy and vaccination, which
issues need to be considered to improve the exosomal
immunogenicity? To the best of our knowledge, these EVs
need to be optimized in terms of (a) the antigen-loading
efficiency, (b) the compositions, morphology and sizes, (c)
the in vivo trafficking, and finally (d) the biological fates
and impacts in the target cells.
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Prospective Highlights
What is current knowledge?
√ Extracellular vesicles (exosomes) are important cellular
micro-/nano-machineries that convey biological information.

10.

11.

√ Cancer-derived exosomes can favor the progression and
development of cancer.

12.

√ Dentric cells-derived exosomes may act against cancer
progression and development.

13.

What is new here?
√ The information of exosomes must be decoded in different
cancers and patients to be used for personalized diagnosis
and therapy.
√ Dentric cells-derived exosomes need to be carefully
designed for cancer immunotherapy and vaccination.
√ For achievement of greater immunotherapy and
vaccination, the antigen-loading efficiency of exosomes
must be improved.
√ The compositions, morphology and sizes of exosomes
may affect their biological impacts.
√ In vivo trafficking and bio-degradation of exosomes must
be fully clarified.

14.

15.

16.

17.

18.
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